| Cellares–SEVERAL: investment, 202105 financing round Series B $82m led by Decheng Capital + Eclipse Ventures |
2021-05-05 |
| Cellares–Skyviews Life Science: investment, 202105 financing round Series B totalling $82m incl new + co-investor Skyviews Life Science |
2021-05-05 |
| Cytoki Pharma–+ND Capital: investment, 202105 financing round Series A totalling $45m incl co-investor +ND Captial |
2021-05-05 |
| Cytoki Pharma–BPCE: investment, 202105 financing round Series A totalling $45m incl co-investor Seventure Partners |
2021-05-05 |
| Cytoki Pharma–Lundbeck: investment, 202105 financing round Series A totalling $45m incl existing + lead investor Lundbeckfonden Emerge |
2021-05-05 |
| Cytoki Pharma–SEVERAL: investment, 202105 financing round Series A $45m led by existing investor Lundbeckfonden Emerge |
2021-05-05 |
| Cytoki Pharma–Ysios Capital: investment, 202105 financing round Series A totalling $45m incl co-investor Ysios Capital |
2021-05-05 |
| Athenex–Cooley: legal services, 202105 supply service Cooley (UK) acted as sole advisor to Athenex with regard to acquisition of Kuur Therapeutics |
2021-05-04 |
| Kuur Therapeutics–Athenex: investment, 202105 acquisition $70m upfront (mainly in shares) + $115m milestones by Athenex |
2021-05-04 |
| Kuur Therapeutics–HMB Legal Counsel: legal services, 202105 supply service HMB Legal legal advisor to Kuur with regard to acquisition by Athenex |
2021-05-04 |
| Kuur Therapeutics–SVB: financial services, 202105 supply service SVB Lerrink financial adivsor to Kuur with regard to acquisition by Athenex |
2021-05-04 |
| Oxford Nanopore–SEVERAL: investment, 202105 financing round £195m from new + existing investors |
2021-05-04 |
| Aquila Biolabs–Scientific Industries: investment, 202104 acquisition of Aquila Biolabs GmbH by Scientific Bioprocessing Inc |
2021-04-30 |
| Adcendo–Gilde Investment: investment, 202104 financing round Series A totalling €51m incl co-investor Gilde Healthcare |
2021-04-29 |
| Adcendo–Novo Group: investment, 202104 financing round Series A totalling €51m incl co-lead investor Novo Seeds |
2021-04-29 |
| Adcendo–Odlander Fredrikson: investment, 202104 financing round Series A totalling €51m incl co-investor RA HealthCap |
2021-04-29 |
| Adcendo–Optimum Strategic Communications: public relations, 202104 service existent by Optimum |
2021-04-29 |
| Adcendo–RA Capital: investment, 202104 financing round Series A totalling €51m incl co-investor RA Capital Management |
2021-04-29 |
| Adcendo–SEVERAL: investment, 202104 financing round Series A €51m co-led by Novo Seeds + Ysios Capital |
2021-04-29 |
| Adcendo–Ysios Capital: investment, 202104 financing round Series A totalling €51m incl co-lead investor Ysios Capital |
2021-04-29 |
| Valneva–SEVERAL: investment, 202104– European private placement ANNOUNCED |
2021-04-29 |
| Valneva–SEVERAL: investment, 202104– US IPO of ADSs at Nasdaq Global Market ANNOUNCED |
2021-04-29 |
| Agendia–Inivata: cancer test, 202104– co-excl distribution rights €na for RaDaR liquid biopsy assay for breast cancer in North America + Europe |
2021-04-28 |
| Kaia Health–3VC: investment, 202104 financing round Series C totalling $75m incl existing + co-investor 3VC |
2021-04-28 |
| Kaia Health–A Round Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor A Round Capital |
2021-04-28 |
| Kaia Health–Balderton Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Balderton Capital |
2021-04-28 |
| Kaia Health–Eurazeo: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Eurazeo |
2021-04-28 |
| Kaia Health–Heartcore Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Heartcore Capital |
2021-04-28 |
| Kaia Health–Hot Cherry PR: public relations, 202104 service existent by Hot Cherry PR |
2021-04-28 |
| Kaia Health–OTHER: investment, 202104 financing round Series C totalling $75m incl undisclosed growth equity fund as lead investor |
2021-04-28 |
| Kaia Health–SEVERAL: investment, 202104 financing round Series C $75m led by undisclosed growth equity fund |
2021-04-28 |
| Kaia Health–Symphony Ventures: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Symphony Ventures |
2021-04-28 |
| Kaia Health–UnitedHealth: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Optum Ventures |
2021-04-28 |
| Exciva–Andera Partners: investment, 202104 existent investment of Andera Partners |
2021-04-27 |
| Exscientia–BlackRock: investment, 202104 financing round Series D totalling $225m incl existing + co-investor BlackRock |
2021-04-27 |
| Exscientia–BMS: investment, 202104 financing round Series D totalling $225m incl existing + co-investor BMS |
2021-04-27 |
| Exscientia–Casdin Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Casdin Capital |
2021-04-27 |
| Exscientia–Farallon Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Farallon Capital |
2021-04-27 |
| Exscientia–GT Healthcare Capital Partners: investment, 202104 financing round Series D totalling $225m incl co-investor GT Healthcare |
2021-04-27 |
| Exscientia–Hongkou: investment, 202104 financing round Series D totalling $225m incl co-investor Hongkou |
2021-04-27 |
| Exscientia–Laurion Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Laurion Capital |
2021-04-27 |
| Exscientia–Marshall Wace: investment, 202104 financing round Series D totalling $225m incl co-investor Marshall Wace |
2021-04-27 |
| Exscientia–Nan Fung: investment, 202104 financing round Series D totalling $225m incl co-investor Pivotal bioVenture Partners |
2021-04-27 |
| Exscientia–Novo Group: investment, 202104 financing round Series D totalling $225m incl existing + co-investor Novo Holdings |
2021-04-27 |
| Exscientia–SEVERAL: investment, 202104 financing round Series D $225m led by SoftBank Vision Fund 2 |
2021-04-27 |
| Exscientia–SoftBank: investment, 202104 financing round Series D totalling $225m incl lead investor SoftBank Vision Fund 2 |
2021-04-27 |
| Exscientia–SoftBank: investment, 202104– equity commitment up to $300m by SoftBank than can be drawn at Exscientia’s discretion |
2021-04-27 |
| Exscientia–United Arab Emirates (govt): investment, 202104 financing round Series D totalling $225m incl co-investor Mubadala Investment Company |
2021-04-27 |
| Mablink Bioscience–SEVERAL: investment, 202104 seed financing round €4m led by Elaia Partners |
2021-04-27 |
| PreComb Therapeutics–FiveT Capital: investment, 202104 seed financing round totalling CHF2.2m incl co-lead investor FiveT Capital |
2021-04-26 |
| PreComb Therapeutics–High-Tech Gründerfonds: investment, 202104 seed financing round totalling CHF2.2m incl co-lead investor HTGF |
2021-04-26 |
| PreComb Therapeutics–Kinled: investment, 202104 seed financing round totalling CHF2.2m incl co-lead investor Kinled Austria |
2021-04-26 |
| PreComb Therapeutics–SEVERAL: investment, 202104 seed financing round CHF2.2m led by Kinled Austria + HTGF + FiveT Capital |
2021-04-26 |
| Molecular Partners–SEVERAL: investment, 202104– US IPO at Nasdaq FILED |
2021-04-23 |
| Anavo Therapeutics–ABP (NL): investment, 202104 seed financing round totalling €20m incl co-lead investor Inkef Capital |
2021-04-22 |
| Anavo Therapeutics–Bioqube Ventures: investment, 202104 seed financing round totalling €20m incl co-investor Bioqube Ventures |
2021-04-22 |
| Anavo Therapeutics–MacDougall Advisors: public relations, 202104 service existent by MacDougall |
2021-04-22 |
| Anavo Therapeutics–Merck (DE): investment, 202104 seed financing round totalling €20m incl co-lead investor M Ventures |
2021-04-22 |
| Anavo Therapeutics–Otsuka: investment, 202104 seed financing round totalling €20m incl co-investor Taiho Ventures |
2021-04-22 |
| Anavo Therapeutics–SEVERAL: investment, 202104 seed financing round €20m led by M Ventures + Inkef Capital |
2021-04-22 |
| Forbion–SEVERAL: investment, 202104 additional €175m + final closing at hard cap of €360m of Forbion Growth Opportunities Fund I |
2021-04-20 |
| Forbion–Wealth Management Partners: investment, 202104 final closing at €360m of Forbion Growth Opportunities Fund I incl investor WMP |
2021-04-20 |
| Gamut Therapeutics–SparingVision: investment, 202104– acquisition €na mainly in shares ANNOUNCED |
2021-04-20 |
| Mestag Therapeutics–JnJ: investment, 202104 seed financing round totalling $11m incl Johnson & Johnson Innovation JJDC Inc |
2021-04-20 |
| Mestag Therapeutics–JW Communications: public relations, 202104 service existent by JW Communications |
2021-04-20 |
| Mestag Therapeutics–SEVERAL: investment, 202104 seed financing round $11m with SV Health Investors + JJDC |
2021-04-20 |
| Mestag Therapeutics–SV Health Investors: investment, 202104 seed financing round totalling $11m incl SV Health Investors |
2021-04-20 |
| Rinri Therapeutics–BioCity (GB): investment, 202104 financing round totalling £10m incl existing investor BioCity |
2021-04-20 |
| Rinri Therapeutics–Boehringer: investment, 202104 financing round totalling £10m incl existing investor BIVF |
2021-04-20 |
| Rinri Therapeutics–SEVERAL: investment, 202104 financing round £10m from existing investors + incl convertible loan from UK Future Fund |
2021-04-20 |
| Rinri Therapeutics–UCB: investment, 202104 financing round totalling £10m incl existing investor UCB Ventures |
2021-04-20 |
| Rinri Therapeutics–United Kingdom (govt): credit, 202104 financing totalling £10m incl convertible loan from UK Future Fund |
2021-04-20 |
| Sense Biodetection–Cambridge Innovation Capital: investment, 202104 financing round Series B totalling $50m incl exisiting + co-investor CIC |
2021-04-20 |
| Sense Biodetection–Earlybird: investment, 202104 financing round Series B totalling $50m incl exisiting + co-investor Earlybird Health |
2021-04-20 |
| Sense Biodetection–Koch Industries: investment, 202104 financing round Series B totalling $50m incl new + lead investor Koch Disruptive Technologies |
2021-04-20 |
| Sense Biodetection–Mercia: investment, 202104 financing round Series B totalling $50m incl exisiting + co-investor Mercia Asset Management |
2021-04-20 |
| Sense Biodetection–PERSON: investment, 202104 financing round Series B totalling $50m incl exisiting + co-investor Jonathan Milner |
2021-04-20 |
| Sense Biodetection–SEVERAL: investment, 202104 financing round Series B $50m led by Koch Disruptive Technologies |
2021-04-20 |
| Synendos Therapeutics–Ysios Capital: investment, 202104 investment by new investor Ysios Capital extends financing round Series A to CHF24m |
2021-04-20 |
| Lumicks–Farallon Capital: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co-lead investor Farallon Capital |
2021-04-16 |
| Lumicks–Gilde Investment: investment, 202104 financing round Series D totalling $93m preferred shares incl existing + co investor Gilde HC |
2021-04-16 |
| Lumicks–Irving Investors: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Irving Investors |
2021-04-16 |
| Lumicks–Lauxera Capital: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co-lead investor Lauxera Capital |
2021-04-16 |
| Lumicks–Parian Global Management: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Parian Global Mgt |
2021-04-16 |
| Lumicks–Pura Vida Investments: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Pura Vida |
2021-04-16 |
| Lumicks–SEVERAL: investment, 202104 financing round Series D $93m preferred shares led by Farallon Capital + Lauxera Capital |
2021-04-16 |
| Lumicks–Softbank: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Softbank Vision 2 |
2021-04-16 |
| Lumicks–T Rowe Price: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor funds managed by T Rowe Price |
2021-04-16 |
| Alchemab–RA Capital: investment, 202104 financing round Series B totalling £60m incl lead investor RA Capital Management |
2021-04-15 |
| Alchemab–SEVERAL: investment, 202104 financing round Series B £60m led by RA Capital Management |
2021-04-15 |
| Alligator Bioscience–MacroGenics: antibody cancer drug, 202104– collab research using Neo-X-Prime plus DART+TRIDENT technologies against two targets |
2021-04-15 |
| ATMPS–Oribiotech: CAGT manufacturing technology, 202104– collab ww for integrated digital patform for CAGT developers using Hataali platform |
2021-04-14 |
| BioVersys–EU (govt): credit, 202104– venture debt loan up to €20m in three tranches from EIB |
2021-04-14 |
| Camtech Diagnostics–Congenica: bioinformatics, 202104– distribution of Congenica’s platform in SG+MY+JP+KR |
2021-04-13 |
| Quercis Pharma–Rx Communications: public relations, 202104 service existent IR by Rx Communications Group |
2021-04-13 |
| Repertoire Immune Medicines–SEVERAL: investment, 202104 financing round Series B $189m incl Flagship Pioneering + Softbank + PSP Investments et al |
2021-04-13 |
| Siemens–Biognosys: MS-based biomarker discovery, 202104– strategic agreem marker discovery using HRM-MS for Dx assay development with S Healthineers |
2021-04-13 |
| Mestex–Grünenthal: investment, 202104 acquisition 100% of Mestex AG by Grünenthal |
2021-04-12 |
| Luminex–DiaSorin: investment, 202104– acquisition $1.8b in cash for $37/share by DiaSorin ANNOUNCED |
2021-04-11 |
| Tidal Therapeutics–Sanofi: investment, 202104 acquisition $160m upfront + $310m milestones by Sanofi |
2021-04-09 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
